New Haven-based BioXcel Therapeutics is expanding its Phase 2 trial of BXCL701, its drug candidate for prostate cancer.
BXCL701 is the company’s investigational, orally administered immune activator for heavily pre-treated metastatic castration-resistant prostate cancer patients with either de novo or treatment-emergent small-cell neuroendocrine carcinoma xxx .